Knight Therapeutics (KHTRF) News Today $4.72 +0.03 (+0.64%) As of 08/27/2025 12:52 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock KHTRF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Knight Therapeutics Gets Exchange Approval for Share Buyback ProgramAugust 22, 2025 | marketwatch.comKnight Therapeutics announces normal course issuer bidAugust 20, 2025 | msn.comKnight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comKnight Therapeutics Reports Second Quarter 2025 ResultsAugust 7, 2025 | globenewswire.comNotice of Knight Therapeutics’ Second Quarter 2025 Results Conference CallAugust 1, 2025 | financialpost.comFNotice of Knight Therapeutics' Second Quarter 2025 Results Conference CallAugust 1, 2025 | globenewswire.comTSX Growth Companies With High Insider Ownership For July 2025July 25, 2025 | uk.finance.yahoo.comKnight Therapeutics Announces Closing of Previously Announced Acquisition of PaladinJune 17, 2025 | globenewswire.comKnight Therapeutics Secures US$50 Million Credit Facility to Fuel GrowthJune 17, 2025 | tipranks.comKnight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian PortfolioJune 5, 2025 | globenewswire.comCanaccord Genuity Keeps Their Buy Rating on Knight Therapeutics (KHTRF)May 12, 2025 | theglobeandmail.comKnight Therapeutics Inc. (KHTRF) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comKnight Therapeutics Inc (KHTRF) Q1 2025 Earnings Call Highlights: Strategic Expansions and ...May 9, 2025 | finance.yahoo.comKnight Therapeutics Reports First Quarter 2025 ResultsMay 8, 2025 | globenewswire.comKnight Therapeutics Inc. announces voting results from the Annual General MeetingMay 7, 2025 | globenewswire.comKnight Therapeutics Announces Relaunch of ONICIT® in Brazil and MexicoMay 7, 2025 | globenewswire.comNotice of Knight Therapeutics’ First Quarter 2025 Results Conference CallMay 1, 2025 | financialpost.comFNotice of Knight Therapeutics' First Quarter 2025 Results Conference CallMay 1, 2025 | globenewswire.comKnight to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 29, 2025 | financialpost.comFWhy I’d Consider These Top Healthcare Stocks for a $10,000 Long-Term InvestmentApril 17, 2025 | ca.finance.yahoo.comKnight Therapeutics Inc. ranks on The Globe and Mail's sixth-annual Women Lead Here benchmark of executive gender diversityMarch 28, 2025 | investing.comKnight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversityMarch 28, 2025 | financialpost.comFKnight Therapeutics Full Year 2024 Earnings: Beats ExpectationsMarch 26, 2025 | finance.yahoo.comStifel Nicolaus Reaffirms Their Buy Rating on Knight Therapeutics (KHTRF)March 25, 2025 | markets.businessinsider.comKnight Therapeutics’ Earnings Call: Record Revenues Amid ChallengesMarch 22, 2025 | msn.comStifel Nicolaus Remains a Buy on Knight Therapeutics (KHTRF)March 21, 2025 | markets.businessinsider.comKnight Therapeutics (KHTRF) Gets a Buy from RBC CapitalMarch 21, 2025 | markets.businessinsider.comKnight Therapeutics sees FY25 revenue C$390M-C$405MMarch 21, 2025 | markets.businessinsider.comKnight Therapeutics reports FY24 EPS C$0.04 vs. (C$0.16) last yearMarch 21, 2025 | markets.businessinsider.comKnight Therapeutics downgraded to Hold from Buy at CanaccordMarch 21, 2025 | markets.businessinsider.comKnight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comKnight Therapeutics Reports Fourth Quarter and Year-End 2024 ResultsMarch 20, 2025 | financialpost.comFKnight Therapeutics Reports Fourth Quarter and Year-End 2024 ResultsMarch 20, 2025 | globenewswire.comEndo, Inc. to Sell International Pharmaceuticals Business to Knight TherapeuticsMarch 14, 2025 | msn.comKnight Therapeutics (KHTRF) Receives a Buy from Stifel NicolausMarch 13, 2025 | markets.businessinsider.comNotice of Knight Therapeutics’ Fourth Quarter and Year End 2024 Results Conference CallMarch 13, 2025 | financialpost.comFNotice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference CallMarch 13, 2025 | globenewswire.comCanaccord Genuity Reaffirms Their Buy Rating on Knight Therapeutics (KHTRF)March 12, 2025 | markets.businessinsider.comKnight Therapeutics to Acquire Paladin Pharma for C$120MMarch 11, 2025 | marketwatch.comKnight Therapeutics to buy Paladin Pharma in bid to build out Canadian businessMarch 11, 2025 | theglobeandmail.comKnight Therapeutics upgraded to Buy from Hold at Mackie Research CapitalMarch 11, 2025 | markets.businessinsider.comKnight Therapeutics to Acquire PaladinMarch 11, 2025 | financialpost.comFKnight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®January 28, 2025 | financialpost.comFKnight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®January 28, 2025 | financialpost.comFKnight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®January 28, 2025 | globenewswire.comKnight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 41% of the shares, institutions hold 24%December 27, 2024 | uk.finance.yahoo.comKnight Therapeutics Announces Regulatory Approval of TAVALISSE® in MexicoDecember 12, 2024 | globenewswire.comKnight Therapeutics price target lowered to C$7.50 from C$8 at Raymond JamesNovember 15, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Knight Therapeutics (KHTRF)November 9, 2024 | markets.businessinsider.comKnight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.com Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KHTRF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KHTRF Media Mentions By Week KHTRF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KHTRF News Sentiment▼1.301.05▲Average Medical News Sentiment KHTRF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KHTRF Articles This Week▼01▲KHTRF Articles Average Week Get the Latest News and Ratings for KHTRF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Knight Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TGIFF News FFNTF News ABSCF News LBTSF News AZFL News ERBB News AVTBF News AVCNF News BIOYF News CBGL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:KHTRF) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KHTRF Stock Alerts